GHP Investment Advisors Inc. Increases Stock Position in Stryker Corporation $SYK

GHP Investment Advisors Inc. raised its stake in shares of Stryker Corporation (NYSE:SYK) by 9.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,190 shares of the medical technology company’s stock after purchasing an additional 3,729 shares during the period. GHP Investment Advisors Inc.’s holdings in Stryker were worth $14,520,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Stryker during the 4th quarter valued at approximately $1,822,272,000. Auto Owners Insurance Co lifted its position in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after buying an additional 1,146,998 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SYK. Jefferies Financial Group restated a “buy” rating and set a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research report on Friday, May 1st. BTIG Research cut their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Evercore set a $355.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, Wells Fargo & Company dropped their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Stock Up 0.9%

Shares of SYK opened at $316.41 on Friday. The firm has a fifty day moving average price of $311.29 and a 200-day moving average price of $339.98. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $121.30 billion, a P/E ratio of 36.62, a P/E/G ratio of 2.01 and a beta of 0.78. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 in the last three months. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.